1
|
Sel FA, Oğuz FS. Can novel methods replace the gold standard chimerism method after allogeneic hematopoietic stem cell transplantation? Ann Hematol 2024; 103:1035-1047. [PMID: 37801085 DOI: 10.1007/s00277-023-05448-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Accepted: 09/07/2023] [Indexed: 10/07/2023]
Abstract
After hematopoietic stem cell transplantation, chimerism assay is a useful approach to monitor the success of the transplant and to select the appropriate treatment strategy, such as donor leukocyte infusion or immunosuppressive drug dosage. Short tandem repeat PCR is the method that has been accepted as the gold standard for chimerism. However, it has not yet been sufficient to detect mixed chimerism in patients with minimal residual disease. Simultaneously, recent years have been marked by developing sensitive, high-throughput, and accurate molecular genetic assays. These novel methods have subsequently been adapted for the analysis of post-transplant chimerism. In this review, we discuss the technical features of both novel and conventional gold standard chimerism assays. We also discuss their advantages and disadvantages.
Collapse
Affiliation(s)
- Figen Abatay Sel
- Department of Biology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.
- Institute of Graduate Studies in Health Science, Istanbul University, Istanbul, Turkey.
| | - Fatma Savran Oğuz
- Department of Biology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
| |
Collapse
|
2
|
Bendjelloul M, Usureau C, Etancelin P, Saidak Z, Lebon D, Garçon L, Marolleau J, Desoutter J, Guillaume N. Utility of assessing
CD3
+
cell chimerism within the first months after allogeneic hematopoietic stem‐cell transplantation for acute myeloid leukemia. HLA 2022; 100:18-23. [PMID: 35064642 PMCID: PMC9303291 DOI: 10.1111/tan.14557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Revised: 12/22/2021] [Accepted: 01/19/2022] [Indexed: 11/30/2022]
Affiliation(s)
- Mehdi Bendjelloul
- Department of Hematology and Histocompatibility Amiens University Medical Center Amiens France
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
| | - Cédric Usureau
- Department of Hematology and Histocompatibility Amiens University Medical Center Amiens France
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
| | | | - Zuzana Saidak
- Laboratory of Molecular Oncobiology, Center of Human Biology, Amiens‐Picardie University Medical Center Amiens France
| | - Delphine Lebon
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
- Department of Clinical Hematology and Cellular Therapy Amiens University Medical Center Amiens France
| | - Loïc Garçon
- Department of Hematology and Histocompatibility Amiens University Medical Center Amiens France
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
| | - Jean‐Pierre Marolleau
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
- Department of Clinical Hematology and Cellular Therapy Amiens University Medical Center Amiens France
| | - Judith Desoutter
- Department of Hematology and Histocompatibility Amiens University Medical Center Amiens France
| | - Nicolas Guillaume
- Department of Hematology and Histocompatibility Amiens University Medical Center Amiens France
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
| |
Collapse
|
3
|
Desoutter J, Usureau C, Jacob V, Lebon D, Caulier A, Da Costa C, Charbonnier A, Joris M, Marolleau JP, Guillaume N. A one-step assay for sorted CD3 + cell purity and chimerism after hematopoietic stem cell transplantation. HLA 2020; 97:183-187. [PMID: 33314632 DOI: 10.1111/tan.14168] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2020] [Revised: 10/06/2020] [Accepted: 12/11/2020] [Indexed: 11/30/2022]
Abstract
A hematopoietic chimerism assay is the laboratory test for monitoring engraftment and quantifying the proportions of donor and recipient cells after hematopoietic stem cell transplantation recipients. Flow cytometry is the reference method for determining the purity of CD3+ cells on the chimerism of selected CD3+ cells. In the present study, we developed a single-step procedure that combines the CD3+ purity assay (using the PCR-based Non-T Genomic Detection Kit from Accumol, Calgary, Canada) and the qPCR chimerism monitoring assay (the QTRACE qPCR assay from Jeta Molecular, Utrecht, the Netherlands). First, for the CD3+ purity assay, we used a PCR-friendly protocol by changing the composition of the ready-to-use reaction tubes (buffer and taq polymerase) and obtained a satisfactory calibration plot (R2 = 0.8924) with a DNA reference scale of 2 ng/μl. Next, 29 samples (before and after CD3 positive selection) were analyzed, the mean cell purity was, respectively, 19.6% ± 6.45 and 98.9% ± 1.07 in the flow cytometry assay; 26.8% ± 7.63 and 98.5% ± 1.79 in the PCR-based non-T genomic detection assay. Our results showed that the CD3+ purity assay using a qPCR kit is a robust alternative to the flow cytometry assay and is associated with time savings when combined with a qPCR chimerism assay.
Collapse
Affiliation(s)
- Judith Desoutter
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| | - Cédric Usureau
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| | - Valentine Jacob
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| | - Delphine Lebon
- EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France.,Department of Clinical Hematology and Cellular Therapy, Amiens University Medical Center, Amiens, France
| | - Alexis Caulier
- EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France.,Department of Clinical Hematology and Cellular Therapy, Amiens University Medical Center, Amiens, France
| | - Cécilia Da Costa
- EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| | - Amandine Charbonnier
- Department of Clinical Hematology and Cellular Therapy, Amiens University Medical Center, Amiens, France
| | - Magalie Joris
- Department of Clinical Hematology and Cellular Therapy, Amiens University Medical Center, Amiens, France
| | - Jean-Pierre Marolleau
- EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France.,Department of Clinical Hematology and Cellular Therapy, Amiens University Medical Center, Amiens, France
| | - Nicolas Guillaume
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| |
Collapse
|
4
|
Donor-derived CD4+/CCR7+ T-cell impact on acute GVHD incidence following haplo-HCT after reduced intensity conditioning and posttransplant cyclophosphamide. Bone Marrow Transplant 2019; 54:1686-1693. [DOI: 10.1038/s41409-019-0511-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2019] [Revised: 02/17/2019] [Accepted: 03/05/2019] [Indexed: 12/16/2022]
|